TRPS1 and neoplasm: miR-221/222 act on its downstream target, trichorhinophalangeal syndrome type 1 (TRPS1), which is an inhibitor of EMT, and miR-221/222 can reduce its expression, thus promoting the epithelial–mesenchymal transition of tumor cells and increasing tumor invasion (89).